Assembly Bio ditches hepatitis B drug on liver toxicity concerns in mid-stage test
Bay Area microcap biotech Assembly Bio had big plans for a lead hepatitis B drug, but safety red flags have now led the company to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
